Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge ...
All content for Beginner's Mind is the property of Christian Soschner and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge ...
EP 156 - Janos Pasztor: The Most Controversial Fix for Climate Change
Beginner's Mind
2 hours 59 minutes
8 months ago
EP 156 - Janos Pasztor: The Most Controversial Fix for Climate Change
What if the only way to save the planet... is to cool it? Not figuratively—literally. Because the heatwaves, floods, and fires you’ve seen so far? They’re just the beginning. 🌍 Emissions keep rising. Global cooperation is slowing. And the window to act is closing fast. Now, world leaders are quietly weighing a radical idea: Should we artificially cool Earth before it’s too late? 💥 In this explosive episode, we dive into the most controversial climate strategy on the table today: solar...
Beginner's Mind
Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge ...
